Treatment of depression with the CRH-1-receptor antagonist R121919: Endocrine changes and side effects

Journal of Psychiatric Research

Volumn 37, Issue 6, 2003, Pages 525-533

  Künzel, Heike E ^a   Zobel, Astrid W ^a   Nickel, Thomas ^a   Ackl, Nibal ^a   Uhr, Manfred ^a   Sonntag, Annette ^a   Ising, Marcus ^a   Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Corticotropin releasing hormone; CRH 1 receptor antagonist; Depression; Side effects

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; ALDOSTERONE; ANTIDEPRESSANT AGENT; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; GROWTH HORMONE; HYDROCORTISONE; LIVER ENZYME; PRASTERONE; THYROID HORMONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD LEVEL; BRADYCARDIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORTICOTROPIN TEST; DATA ANALYSIS; DECELERATION; DRUG URINE LEVEL; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; FEMALE; HEADACHE; HORMONE DETERMINATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; LABORATORY TEST; LOW BACK PAIN; MAJOR DEPRESSION; MALE; NAUSEA; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROLACTIN RELEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUICIDAL BEHAVIOR; TACHYCARDIA; UROGENITAL TRACT INFECTION; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE; VERTIGO;

EID: 0141957372     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(03)00070-0     Document Type: Article

References (46)

1. Aguilera G., Millan M.A., Hauger R.L., Catt K.J. Corticotropin-releasing factor receptors. distribution and regulation in brain, pituitary, and peripheral tissues Annals New York Academy of Sciences. 512:1987;48-66.
2. Barbarino A., Corsello S.M., Della Casa S., Tofani A., Sciuto R., Rota C.A.et al. Corticotropin-releasing hormone inhibition of growth hormone-releasing hormone-induced growth hormone release in man. Journal of Clinical Endocrinology and Metabolism. 71:1990;1368-1374.
3. Chen C., Dagnino R.J., De Souza E.B., Grigoriadis D.E., Huang C.Q., Kim K.I.et al. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. Journal of Medical Chemistry. 39:1996;4358-4360.
4. Haggerty J.J. Jr., Prange A.J. Jr. Borderline hypothyroidism and depression. Annual Review of Medicine. 46:1995;37-46.
5. Halbreich U., Asnis G.M., Shindledecker R., Zumoff B., Nathan R.S. Cortisol secretion in endogenous depression. I. Basal plasma levels. Archives of General Psychiatry. 42:1985;904-908.
6. Hartline K.M., Owens M.J., Nemeroff C.B. Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Annals of the New York Academy of Sciences. 780:1996;96-105.
7. Heinrichs S.C., De Souza E.B., Schulteis G., Lapsansky J.L., Grigoriadis D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 27:2002;194-202.
8. Heuser I., Yassouridis A., Holsboer F. The combined dexamethasone/CRH test. a refined laboratory test for psychiatric disorders Journal of Psychiatric Research. 28:1994;341-356.
9. Heuser I.J., Schweiger U., Gotthardt U.et al. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. American Journal of Psychiatry. 153:1996;93-99.
10. Holsboer F. Corticotropin-releasing hormone - a new tool to investigate hypothalamic-pituitary-adrenocortical physiology in psychiatric patients. Psychopharmacological Bulletin. 22:1986;907-912.
11. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Reviews. 17:1996;187-205.
12. Holsboer-Trachsler E., Hemmeter U., Hatzinger M., Seifritz E., Gerhard U., Hobi V. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment - neurobiological and psychometric assessment of course. Journal of Psychiatric Research. 28:1994;381-399.
13. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Journal of Psychiatric Research. 33:1999;181-214.
14. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501.
15. Jackson I.M. The thyroid axis and depression. Thyroid. 8:1998;951-956.
16. Keck M.E., Welt T., Wigger A.et al. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. European Journal of Neuroscience. 13:2001;373-380.
17. 1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin and testosterone secretion. Pharmacopsychiatry. 36:2003;27-31.
18. Lesch K.P., Rupprecht R., Muller U., Pfuller H., Beckmann H. Insulin-like growth factor I in depressed patients and controls. Acta Psychiatrica Scandinavica. 78:1988;684-688.
19. Liebsch G., Landgraf R., Engelmann M., Lorscher P., Holsboer F. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. Journal of Psychiatric Research. 33:1999;153-163.
20. Liebsch G., Landgraf R., Gerstberger R.et al. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regulatory Peptides. 59:1995;229-239.
21. Meller W.H., Grambsch P.L., Bingham C., Tagatz G.E. Hypothalamic pituitary gonadal axis dysregulation in depressed women. Psychoneuroendocrinology. 26:2001;253-259.
22. Nemeroff C.B., Widerlov E., Bissette G.et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 226:1984;1342-1344.
23. Owens M.J., Nemeroff C.B. Corticotropin-releasing factor antagonists in affective disorders. Expert Opinion on Investigational Drugs. 8:1999;1849-1858.
24. Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacological Review. 43(4):1991;425-473.
25. Radulovic J., Blank T., Eckart K., Radulovic M., Stiedl O., Spiess J. CRF and CRF receptors. Results and Problems in Cell Differentiation. 26:1999;67-90.
26. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Current Opinion in Pharmacology. 2:2002;23-33.
27. Rubin R.T., Phillips J.J. Adrenal gland enlargement in major depression. Archives of General Psychiatry. 50:1993;833-835.
28. Rubin R.T., Phillips J.J., McCracken J.T., Sadow T.F. Adrenal gland volume in major depression. relationship to basal and stimulated pituitary-adrenal cortical axis function Biological Psychiatry. 40:1996;89-97.
29. Rupprecht R., Barocka A., Jecht E., Noder M., Pichl J., Schwarz W. Prolactin response to dexamethasone. a study on normal controls and depressed patients Acta Psychiatrica Scandinavica. 76:1987;139-143.
30. Sanchez M.M., Young L.J., Plotsky P.M., Insel T.R. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. Journal Comparative Neurology. 408:1999;365-377.
31. Schweiger U., Deuschle M., Weber B.et al. Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosomatic Medicine. 61:1999;292-296.
32. Scott L.V., Dinan T.G. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function. implications for the pathophysiology of depression Life Science. 62:1998;1985-1998.
33. Skutella T., Criswell H., Moy S.et al. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rat. Neuroreport. 5:1994;2181-2185.
34. Skutella T., Probst J.C., Renner U., Holsboer F., Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience. 85:1998;795-805.
35. Smith G.W., Aubry J.M., Dellu F.et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20:1998;1093-1102.
36. Steiger A., Holsboer F. Neuropeptides and human sleep. Sleep. 20:1997;1038-1052.
37. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice. a genetic model of anxiogenic behavior Journal of Neuroscience. 14:1994;2579-2584.
38. Torner L., Toschi N., Pohlinger A., Landgraf R., Neumann I.D. Anxiolytic and anti-stress effects of brain prolactin. improved efficacy of antisense targeting of the prolactin receptor by molecular modeling Journal of Neuroscience. 21:2001;3207-3214.
39. Van Gaalen M.M., Stenzel-Poore M.P., Holsboer F., Steckler T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. European Journal of Neuroscience. 15:2002;2007-2015.
40. Van Londen L., Goekoop J.G., van Kempen G.M.et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology. 17:1997;284-292.
41. Von Bardeleben U., Holsboer F., Stalla G.K., Muller O.A. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Science. 37:1985;1613-1618.
42. Wiedemann K., von Bardeleben U., Holsboer F. Influence of human corticotropin-releasing hormone and adrenocorticotropin upon spontaneous growth hormone secretion. Neuroendocrinology. 54:1991;462-468.
43. Wotjak C. T KubotaM, Liebsch G etal. Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion? Journal of Neuroscience. 16:1996;7725-7732.
44. Young E., Korszun A. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-gonadal axis. The Psychiatric Clinics of North America. 21:1998;309-323.
45. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M.et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression. the first 20 patients treated Journal of Psychiatric Research. 34:2000;171-181.
46. Zobel A. W NickelT, Sonntag A UhrM, Holsboer F IsingM Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. Journal of Psychiatric Research. 35:2001;83-94.